Effectiveness of antidepressants - Meta-analysis of dose-effect relationships in randomised clinical trials

被引:214
作者
Bollini, P
Pampallona, S
Tibaldi, G
Kupelnick, B
Munizza, C
机构
[1] Ctr Studi & Rich Psichiatria, I-10154 Turin, Italy
[2] ForMed, Evolene, Switzerland
关键词
D O I
10.1192/bjp.174.4.297
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Antidepressant drugs are usually prescribed at low doses, possibly to avoid adverse reactions. No comprehensive review has addressed the issue of dose, clinical response and tolerability in a quantitative way. Aims To determine whether high doses of antidepressants are more effective than lowdoses, and how safety is affected by dose. Method Trials comparing two or more doses of the same antidepressant were located, and all antidepressants administered were converted to the equivalent dose of imipramine. Generalised estimating equations were used to analyse percentage improvement and adverse event rate according to dose level. Results Thirty-three studies were identified. The dose level 100-200 mg imipramine equivalents showed an average improvement of 53% by 'intention-to-treat', Higher doses were not accompanied by increased efficacy, while lower doses showed reduction in efficacy. Adverse events significantly increased with dose. Conclusions With a low dose of antidepressants, clinicians trade off a slightly reduced chance of improvement for a higher chance of avoiding adverse reactions.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 75 条
  • [11] BEASLEY CM, 1992, J CLIN PSYCHOPHARM, V12, P328
  • [12] Dose escalation vs. Continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response
    Benkert, O
    Szegedi, A
    Wetzel, H
    Staab, HJ
    Meister, W
    Philipp, M
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1997, 95 (04) : 288 - 296
  • [13] Minimum effective dose for antidepressants - An obligatory requirement for antidepressant drug evaluation?
    Benkert, O
    Szegedi, A
    Wetzel, H
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 (03) : 177 - 185
  • [14] BENNIE EH, 1998, HUMAN PSYCHOPHARMACO, V3, P275
  • [15] CLINICAL AND BIOCHEMICAL EFFECTS OF CITALOPRAM, A SELECTIVE 5-HT REUPTAKE INHIBITOR - A DOSE-RESPONSE STUDY IN DEPRESSED-PATIENTS
    BJERKENSTEDT, L
    EDMAN, G
    FLYCKT, L
    HAGENFELDT, L
    SEDVALL, G
    WIESEL, FA
    [J]. PSYCHOPHARMACOLOGY, 1985, 87 (03) : 253 - 259
  • [16] CONTROLLED TRIAL OF AMITRIPTYLINE IN GENERAL PRACTICE
    BLASHKI, TG
    MOWBRAY, R
    DAVIES, B
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1971, 1 (5741): : 133 - +
  • [17] BRANCONNIER RJ, 1983, J CLIN PSYCHIAT, V44, P130
  • [18] ANTIDEPRESSANTS MAY NOT ASSIST RECOVERY IN PRACTICE - A NATURALISTIC PROSPECTIVE SURVEY
    BRUGHA, TS
    BEBBINGTON, PE
    MACCARTHY, B
    STURT, E
    WYKES, T
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1992, 86 (01) : 5 - 11
  • [19] DAMICO MF, 1990, PSYCHOPHARMACOL BULL, V26, P147
  • [20] AN EVALUATION OF 2 DOSES OF ISOCARBOXAZID IN DEPRESSION
    DAVIDSON, J
    MILLER, R
    TURNBULL, CD
    BELYEA, M
    STRICKLAND, R
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1984, 6 (02) : 201 - 207